Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique Article Swipe
Le diabète de type 2 (DT2) est une maladie qui affecte de plus en plus de personnes à travers le monde et comporte plusieurs complications. Les moyens thérapeutiques actuels sont assez limités, car même s'ils sont efficaces, ils sont associés à d'importants effets secondaires. Ainsi, il est important de trouver de nouvelles cibles thérapeutiques pour améliorer la sensibilité à l'insuline en situation d'obésité ou de diabète. Nous nous intéressons ici à une nouvelle cible potentielle, appelée SHP2, qui est une protéine tyrosine phosphatase impliquée dans la transduction du signal en régulant plusieurs voies canoniques (MAPK, PI3K). Cette protéine est connue pour ses rôles cruciaux dans le développement ainsi que son implication dans le métabolisme glucidique. Cependant, cette dernière fonction est encore assez peu comprise, car l'effet d'une délétion de SHP2 sur la sensibilité à l'insuline est différent suivant les tissus et son rôle global n'est pas connu. Nous utilisons ici un modèle original pour étudier l'impact de SHP2 sur le métabolisme glucidique au niveau du corps entier, en travaillant sur le syndrome de Noonan (SN). En effet, cette maladie génétique est principalement causée par une mutation hyperactivatrice du gène PTPN11 codant la protéine SHP2. L'étude du métabolisme glucidique dans le contexte du SN a permis de mettre en évidence une intolérance au glucose, qui est dissociée de l'adiposité réduite, à la fois chez les patients et dans le modèle murin de la maladie (SHP2D61G/+). Nous montrons que les souris SN présentent une inflammation caractérisée par une surexpression de marqueurs pro-inflammatoires, ainsi qu'une augmentation de macrophages pro-inflammatoires dans les tissus métaboliques. Grâce à des expériences de transplantation de moelle osseuse et de traitement au clodronate, nous mettons en évidence que cette inflammation est d'origine macrophagique et est la cause de la résistance à l'insuline présente dans le SN. De plus, nous démontrons que l'hyperactivation de SHP2 induit une hyperactivation des macrophages. De façon intéressante, un traitement avec un inhibiteur de SHP2 améliore fortement le métabolisme glucidique de souris sauvages obèses et diabétiques. Ainsi, ce travail de thèse a permis d'identifier un phénotype original chez les patients et les souris SN associant une insulino-résistance dissociée de l'adiposité, ainsi qu'un rôle clé des macrophages dans ce phénotype. De plus, au-delà de la maladie rare, nous montrons que dans un contexte d'obésité et de DT2, l'inhibition de SHP2 améliore grandement le phénotype métabolique des souris suggérant que SHP2 pourrait être une cible efficace dans le traitement de l'insulino-résistance.
Related Topics
Concepts
Metadata
- Type
- dissertation
- Language
- fr
- http://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdf
- OA Status
- green
- OpenAlex ID
- https://openalex.org/W2941033863
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2941033863Canonical identifier for this work in OpenAlex
- Title
-
Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidiqueWork title
- Type
-
dissertationOpenAlex work type
- Language
-
frPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-11-13Full publication date if available
- Authors
-
Romain PaccoudList of authors in order
- PDF URL
-
https://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdfDirect OA link when available
- Concepts
-
Molecular biology, Chemistry, BiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W2941033863 |
|---|---|
| doi | |
| ids.mag | 2941033863 |
| ids.openalex | https://openalex.org/W2941033863 |
| fwci | |
| type | dissertation |
| title | Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T12104 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1312 |
| topics[0].subfield.display_name | Molecular Biology |
| topics[0].display_name | Protein Tyrosine Phosphatases |
| topics[1].id | https://openalex.org/T12387 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9918000102043152 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Galectins and Cancer Biology |
| topics[2].id | https://openalex.org/T11150 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.983299970626831 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1307 |
| topics[2].subfield.display_name | Cell Biology |
| topics[2].display_name | Endoplasmic Reticulum Stress and Disease |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C153911025 |
| concepts[0].level | 1 |
| concepts[0].score | 0.648268461227417 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7202 |
| concepts[0].display_name | Molecular biology |
| concepts[1].id | https://openalex.org/C185592680 |
| concepts[1].level | 0 |
| concepts[1].score | 0.4018157124519348 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[1].display_name | Chemistry |
| concepts[2].id | https://openalex.org/C86803240 |
| concepts[2].level | 0 |
| concepts[2].score | 0.2829749882221222 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[2].display_name | Biology |
| keywords[0].id | https://openalex.org/keywords/molecular-biology |
| keywords[0].score | 0.648268461227417 |
| keywords[0].display_name | Molecular biology |
| keywords[1].id | https://openalex.org/keywords/chemistry |
| keywords[1].score | 0.4018157124519348 |
| keywords[1].display_name | Chemistry |
| keywords[2].id | https://openalex.org/keywords/biology |
| keywords[2].score | 0.2829749882221222 |
| keywords[2].display_name | Biology |
| language | fr |
| locations[0].id | pmh:oai:thesesups.ups-tlse.fr:4181 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306400942 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Thèses en ligne de l'Université Toulouse III (Université Toulouse III) |
| locations[0].source.host_organization | https://openalex.org/I134560555 |
| locations[0].source.host_organization_name | Université Toulouse III - Paul Sabatier |
| locations[0].source.host_organization_lineage | https://openalex.org/I134560555 |
| locations[0].license | |
| locations[0].pdf_url | http://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdf |
| locations[0].version | submittedVersion |
| locations[0].raw_type | PhD Thesis |
| locations[0].license_id | |
| locations[0].is_accepted | False |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | |
| locations[1].id | pmh:oai:HAL:tel-02381678v2 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306402512 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| locations[1].source.host_organization | https://openalex.org/I1294671590 |
| locations[1].source.host_organization_name | Centre National de la Recherche Scientifique |
| locations[1].source.host_organization_lineage | https://openalex.org/I1294671590 |
| locations[1].license | other-oa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Theses |
| locations[1].license_id | https://openalex.org/licenses/other-oa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Médecine humaine et pathologie. Université Paul Sabatier - Toulouse III, 2018. Français. ⟨NNT : 2018TOU30242⟩ |
| locations[1].landing_page_url | https://theses.hal.science/tel-02381678 |
| locations[2].id | pmh:2018TOU30242 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400553 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) |
| locations[2].source.host_organization | https://openalex.org/I8204097 |
| locations[2].source.host_organization_name | Ludwig-Maximilians-Universität München |
| locations[2].source.host_organization_lineage | https://openalex.org/I8204097 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Electronic Thesis or Dissertation |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | http://www.theses.fr/2018TOU30242/document |
| locations[3].id | mag:2941033863 |
| locations[3].is_oa | False |
| locations[3].source | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | |
| locations[3].raw_type | |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://hal-univ-tlse3-archives-ouvertes-fr.ezproxy.u-pec.fr/tel-02381678 |
| authorships[0].author.id | https://openalex.org/A5085175093 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5780-8639 |
| authorships[0].author.display_name | Romain Paccoud |
| authorships[0].affiliations[0].raw_affiliation_string | Institut des Maladies Métaboliques et Cardiovasculaires |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Romain Paccoud |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Institut des Maladies Métaboliques et Cardiovasculaires |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | http://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T04:12:42.849631 |
| primary_topic.id | https://openalex.org/T12104 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1312 |
| primary_topic.subfield.display_name | Molecular Biology |
| primary_topic.display_name | Protein Tyrosine Phosphatases |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | pmh:oai:thesesups.ups-tlse.fr:4181 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306400942 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Thèses en ligne de l'Université Toulouse III (Université Toulouse III) |
| best_oa_location.source.host_organization | https://openalex.org/I134560555 |
| best_oa_location.source.host_organization_name | Université Toulouse III - Paul Sabatier |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I134560555 |
| best_oa_location.license | |
| best_oa_location.pdf_url | http://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdf |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | PhD Thesis |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | |
| primary_location.id | pmh:oai:thesesups.ups-tlse.fr:4181 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306400942 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Thèses en ligne de l'Université Toulouse III (Université Toulouse III) |
| primary_location.source.host_organization | https://openalex.org/I134560555 |
| primary_location.source.host_organization_name | Université Toulouse III - Paul Sabatier |
| primary_location.source.host_organization_lineage | https://openalex.org/I134560555 |
| primary_location.license | |
| primary_location.pdf_url | http://thesesups.ups-tlse.fr/4181/1/2018TOU30242.pdf |
| primary_location.version | submittedVersion |
| primary_location.raw_type | PhD Thesis |
| primary_location.license_id | |
| primary_location.is_accepted | False |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | |
| publication_date | 2018-11-13 |
| publication_year | 2018 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 4 |
| abstract_inverted_index.a | 203, 336 |
| abstract_inverted_index.De | 297, 310, 364 |
| abstract_inverted_index.En | 175 |
| abstract_inverted_index.Le | 0 |
| abstract_inverted_index.SN | 202, 239, 348 |
| abstract_inverted_index.au | 162, 211, 272 |
| abstract_inverted_index.ce | 332, 362 |
| abstract_inverted_index.de | 2, 11, 15, 48, 50, 64, 128, 156, 172, 205, 216, 230, 247, 253, 264, 266, 270, 288, 303, 318, 325, 334, 353, 367, 379, 382, 402 |
| abstract_inverted_index.du | 87, 164, 187, 195, 201 |
| abstract_inverted_index.en | 13, 60, 89, 167, 207, 276 |
| abstract_inverted_index.et | 21, 140, 225, 269, 284, 329, 345, 378 |
| abstract_inverted_index.il | 45 |
| abstract_inverted_index.la | 56, 85, 131, 191, 220, 231, 286, 289, 368 |
| abstract_inverted_index.le | 19, 105, 112, 159, 170, 199, 227, 295, 322, 386, 400 |
| abstract_inverted_index.ou | 63 |
| abstract_inverted_index.un | 150, 313, 316, 339, 375 |
| abstract_inverted_index.à | 17, 40, 58, 70, 133, 219, 261, 291 |
| abstract_inverted_index.Les | 25 |
| abstract_inverted_index.SN. | 296 |
| abstract_inverted_index.car | 32, 124 |
| abstract_inverted_index.des | 262, 308, 359, 389 |
| abstract_inverted_index.est | 6, 46, 78, 98, 119, 135, 180, 214, 281, 285 |
| abstract_inverted_index.ici | 69, 149 |
| abstract_inverted_index.ils | 37 |
| abstract_inverted_index.les | 138, 223, 237, 257, 343, 346 |
| abstract_inverted_index.par | 183, 244 |
| abstract_inverted_index.pas | 145 |
| abstract_inverted_index.peu | 122 |
| abstract_inverted_index.que | 108, 236, 278, 301, 373, 392 |
| abstract_inverted_index.qui | 9, 77, 213 |
| abstract_inverted_index.ses | 101 |
| abstract_inverted_index.son | 109, 141 |
| abstract_inverted_index.sur | 130, 158, 169 |
| abstract_inverted_index.une | 7, 71, 79, 184, 209, 241, 245, 306, 350, 396 |
| abstract_inverted_index.DT2, | 380 |
| abstract_inverted_index.Nous | 66, 147, 234 |
| abstract_inverted_index.SHP2 | 129, 157, 304, 319, 383, 393 |
| abstract_inverted_index.avec | 315 |
| abstract_inverted_index.chez | 222, 342 |
| abstract_inverted_index.clé | 358 |
| abstract_inverted_index.dans | 84, 104, 111, 198, 226, 256, 294, 361, 374, 399 |
| abstract_inverted_index.fois | 221 |
| abstract_inverted_index.nous | 67, 274, 299, 371 |
| abstract_inverted_index.plus | 12, 14 |
| abstract_inverted_index.pour | 54, 100, 153 |
| abstract_inverted_index.sont | 29, 35, 38 |
| abstract_inverted_index.type | 3 |
| abstract_inverted_index.(DT2) | 5 |
| abstract_inverted_index.(SN). | 174 |
| abstract_inverted_index.Cette | 96 |
| abstract_inverted_index.SHP2, | 76 |
| abstract_inverted_index.SHP2. | 193 |
| abstract_inverted_index.ainsi | 107, 250, 355 |
| abstract_inverted_index.assez | 30, 121 |
| abstract_inverted_index.cause | 287 |
| abstract_inverted_index.cette | 116, 177, 279 |
| abstract_inverted_index.cible | 73, 397 |
| abstract_inverted_index.corps | 165 |
| abstract_inverted_index.d'une | 126 |
| abstract_inverted_index.gène | 188 |
| abstract_inverted_index.monde | 20 |
| abstract_inverted_index.murin | 229 |
| abstract_inverted_index.même | 33 |
| abstract_inverted_index.n'est | 144 |
| abstract_inverted_index.plus, | 298, 365 |
| abstract_inverted_index.qu'un | 356 |
| abstract_inverted_index.rare, | 370 |
| abstract_inverted_index.rôle | 142, 357 |
| abstract_inverted_index.s'ils | 34 |
| abstract_inverted_index.voies | 92 |
| abstract_inverted_index.être | 395 |
| abstract_inverted_index.(MAPK, | 94 |
| abstract_inverted_index.Ainsi, | 44, 331 |
| abstract_inverted_index.Grâce | 260 |
| abstract_inverted_index.Noonan | 173 |
| abstract_inverted_index.PI3K). | 95 |
| abstract_inverted_index.PTPN11 | 189 |
| abstract_inverted_index.cibles | 52 |
| abstract_inverted_index.codant | 190 |
| abstract_inverted_index.connu. | 146 |
| abstract_inverted_index.connue | 99 |
| abstract_inverted_index.effet, | 176 |
| abstract_inverted_index.effets | 42 |
| abstract_inverted_index.encore | 120 |
| abstract_inverted_index.façon | 311 |
| abstract_inverted_index.global | 143 |
| abstract_inverted_index.induit | 305 |
| abstract_inverted_index.mettre | 206 |
| abstract_inverted_index.moelle | 267 |
| abstract_inverted_index.moyens | 26 |
| abstract_inverted_index.niveau | 163 |
| abstract_inverted_index.permis | 204, 337 |
| abstract_inverted_index.qu'une | 251 |
| abstract_inverted_index.rôles | 102 |
| abstract_inverted_index.signal | 88 |
| abstract_inverted_index.souris | 238, 326, 347, 390 |
| abstract_inverted_index.thèse | 335 |
| abstract_inverted_index.tissus | 139, 258 |
| abstract_inverted_index.actuels | 28 |
| abstract_inverted_index.affecte | 10 |
| abstract_inverted_index.causée | 182 |
| abstract_inverted_index.entier, | 166 |
| abstract_inverted_index.l'effet | 125 |
| abstract_inverted_index.maladie | 8, 178, 232, 369 |
| abstract_inverted_index.mettons | 275 |
| abstract_inverted_index.modèle | 151, 228 |
| abstract_inverted_index.obèses | 328 |
| abstract_inverted_index.osseuse | 268 |
| abstract_inverted_index.suivant | 137 |
| abstract_inverted_index.travail | 333 |
| abstract_inverted_index.travers | 18 |
| abstract_inverted_index.trouver | 49 |
| abstract_inverted_index.L'étude | 194 |
| abstract_inverted_index.appelée | 75 |
| abstract_inverted_index.au-delà | 366 |
| abstract_inverted_index.comporte | 22 |
| abstract_inverted_index.contexte | 200, 376 |
| abstract_inverted_index.cruciaux | 103 |
| abstract_inverted_index.diabète | 1 |
| abstract_inverted_index.efficace | 398 |
| abstract_inverted_index.fonction | 118 |
| abstract_inverted_index.glucose, | 212 |
| abstract_inverted_index.l'impact | 155 |
| abstract_inverted_index.montrons | 235, 372 |
| abstract_inverted_index.mutation | 185 |
| abstract_inverted_index.nouvelle | 72 |
| abstract_inverted_index.original | 152, 341 |
| abstract_inverted_index.patients | 224, 344 |
| abstract_inverted_index.pourrait | 394 |
| abstract_inverted_index.sauvages | 327 |
| abstract_inverted_index.syndrome | 171 |
| abstract_inverted_index.tyrosine | 81 |
| abstract_inverted_index.étudier | 154 |
| abstract_inverted_index.améliore | 320, 384 |
| abstract_inverted_index.associant | 349 |
| abstract_inverted_index.associés | 39 |
| abstract_inverted_index.comprise, | 123 |
| abstract_inverted_index.d'origine | 282 |
| abstract_inverted_index.dernière | 117 |
| abstract_inverted_index.diabète. | 65 |
| abstract_inverted_index.fortement | 321 |
| abstract_inverted_index.important | 47 |
| abstract_inverted_index.limités, | 31 |
| abstract_inverted_index.marqueurs | 248 |
| abstract_inverted_index.nouvelles | 51 |
| abstract_inverted_index.personnes | 16 |
| abstract_inverted_index.plusieurs | 23, 91 |
| abstract_inverted_index.protéine | 80, 97, 192 |
| abstract_inverted_index.présente | 293 |
| abstract_inverted_index.réduite, | 218 |
| abstract_inverted_index.régulant | 90 |
| abstract_inverted_index.situation | 61 |
| abstract_inverted_index.utilisons | 148 |
| abstract_inverted_index.évidence | 208, 277 |
| abstract_inverted_index.Cependant, | 115 |
| abstract_inverted_index.améliorer | 55 |
| abstract_inverted_index.canoniques | 93 |
| abstract_inverted_index.différent | 136 |
| abstract_inverted_index.dissociée | 215, 352 |
| abstract_inverted_index.délétion | 127 |
| abstract_inverted_index.efficaces, | 36 |
| abstract_inverted_index.glucidique | 161, 197, 324 |
| abstract_inverted_index.grandement | 385 |
| abstract_inverted_index.impliquée | 83 |
| abstract_inverted_index.inhibiteur | 317 |
| abstract_inverted_index.l'insuline | 59, 134, 292 |
| abstract_inverted_index.phénotype | 340, 387 |
| abstract_inverted_index.suggérant | 391 |
| abstract_inverted_index.traitement | 271, 314, 401 |
| abstract_inverted_index.clodronate, | 273 |
| abstract_inverted_index.d'obésité | 62, 377 |
| abstract_inverted_index.démontrons | 300 |
| abstract_inverted_index.glucidique. | 114 |
| abstract_inverted_index.génétique | 179 |
| abstract_inverted_index.implication | 110 |
| abstract_inverted_index.macrophages | 254, 360 |
| abstract_inverted_index.phosphatase | 82 |
| abstract_inverted_index.phénotype. | 363 |
| abstract_inverted_index.présentent | 240 |
| abstract_inverted_index.résistance | 290 |
| abstract_inverted_index.travaillant | 168 |
| abstract_inverted_index.augmentation | 252 |
| abstract_inverted_index.d'identifier | 338 |
| abstract_inverted_index.d'importants | 41 |
| abstract_inverted_index.expériences | 263 |
| abstract_inverted_index.inflammation | 242, 280 |
| abstract_inverted_index.intolérance | 210 |
| abstract_inverted_index.intéressons | 68 |
| abstract_inverted_index.l'adiposité | 217 |
| abstract_inverted_index.l'inhibition | 381 |
| abstract_inverted_index.macrophages. | 309 |
| abstract_inverted_index.métabolique | 388 |
| abstract_inverted_index.métabolisme | 113, 160, 196, 323 |
| abstract_inverted_index.potentielle, | 74 |
| abstract_inverted_index.secondaires. | 43 |
| abstract_inverted_index.sensibilité | 57, 132 |
| abstract_inverted_index.transduction | 86 |
| abstract_inverted_index.(SHP2D61G/+). | 233 |
| abstract_inverted_index.diabétiques. | 330 |
| abstract_inverted_index.l'adiposité, | 354 |
| abstract_inverted_index.macrophagique | 283 |
| abstract_inverted_index.surexpression | 246 |
| abstract_inverted_index.caractérisée | 243 |
| abstract_inverted_index.complications. | 24 |
| abstract_inverted_index.développement | 106 |
| abstract_inverted_index.intéressante, | 312 |
| abstract_inverted_index.métaboliques. | 259 |
| abstract_inverted_index.principalement | 181 |
| abstract_inverted_index.hyperactivation | 307 |
| abstract_inverted_index.thérapeutiques | 27, 53 |
| abstract_inverted_index.transplantation | 265 |
| abstract_inverted_index.hyperactivatrice | 186 |
| abstract_inverted_index.l'hyperactivation | 302 |
| abstract_inverted_index.pro-inflammatoires | 255 |
| abstract_inverted_index.pro-inflammatoires, | 249 |
| abstract_inverted_index.insulino-résistance | 351 |
| abstract_inverted_index.l'insulino-résistance. | 403 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5085175093 |
| countries_distinct_count | 0 |
| institutions_distinct_count | 1 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile |